Yu A An1, Shiuhwei Chen1, Yingfeng Deng1, Zhao V Wang2, Jan-Bernd Funcke1, Manasi Shah3, Bo Shan1, Ruth Gordillo1, Jun Yoshino4, Samuel Klein4, Christine M Kusminski1, Philipp E Scherer5. 1. Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA. 5. Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: Philipp.Scherer@UTSouthwestern.edu.
Abstract
BACKGROUND & AIMS: We have previously reported that the mitochondrial dicarboxylate carrier (mDIC [SLC25A10]) is predominantly expressed in the white adipose tissue (WAT) and subject to regulation by metabolic cues. However, the specific physiological functions of mDIC and the reasons for its abundant presence in adipocytes are poorly understood. METHODS: To systemically investigate the impact of mDIC function in adipocytes in vivo, we generated loss- and gain-of-function mouse models, selectively eliminating or overexpressing mDIC in mature adipocytes, respectively. RESULTS: In in vitro differentiated white adipocytes, mDIC is responsible for succinate transport from the mitochondrial matrix to the cytosol, from where succinate can act on the succinate receptor SUCNR1 and inhibit lipolysis by dampening the cAMP- phosphorylated hormone-sensitive lipase (pHSL) pathway. We eliminated mDIC expression in adipocytes in a doxycycline (dox)-inducible manner (mDICiKO) and demonstrated that such a deletion results in enhanced adipocyte lipolysis and promotes high-fat diet (HFD)-induced adipocyte dysfunction, liver lipotoxicity, and systemic insulin resistance. Conversely, in a mouse model with dox-inducible, adipocyte-specific overexpression of mDIC (mDICiOE), we observed suppression of adipocyte lipolysis both in vivo and ex vivo. mDICiOE mice are potently protected from liver lipotoxicity upon HFD feeding. Furthermore, they show resistance to HFD-induced weight gain and adipose tissue expansion with concomitant improvements in glucose tolerance and insulin sensitivity. Beyond our data in rodents, we found that human WAT SLC25A10 mRNA levels are positively correlated with insulin sensitivity and negatively correlated with intrahepatic triglyceride levels, suggesting a critical role of mDIC in regulating overall metabolic homeostasis in humans as well. CONCLUSIONS: In summary, we highlight that mDIC plays an essential role in governing adipocyte lipolysis and preventing liver lipotoxicity in response to a HFD. LAY SUMMARY: Dysfunctional fat tissue plays an important role in the development of fatty liver disease and liver injury. Our present study identifies a mitochondrial transporter, mDIC, which tightly controls the release of free fatty acids from adipocytes to the liver through the export of succinate from mitochondria. We believe this mDIC-succinate axis could be targeted for the treatment of fatty liver disease.
BACKGROUND & AIMS: We have previously reported that the mitochondrial dicarboxylate carrier (mDIC [SLC25A10]) is predominantly expressed in the white adipose tissue (WAT) and subject to regulation by metabolic cues. However, the specific physiological functions of mDIC and the reasons for its abundant presence in adipocytes are poorly understood. METHODS: To systemically investigate the impact of mDIC function in adipocytes in vivo, we generated loss- and gain-of-function mouse models, selectively eliminating or overexpressing mDIC in mature adipocytes, respectively. RESULTS: In in vitro differentiated white adipocytes, mDIC is responsible for succinate transport from the mitochondrial matrix to the cytosol, from where succinate can act on the succinate receptor SUCNR1 and inhibit lipolysis by dampening the cAMP- phosphorylated hormone-sensitive lipase (pHSL) pathway. We eliminated mDIC expression in adipocytes in a doxycycline (dox)-inducible manner (mDICiKO) and demonstrated that such a deletion results in enhanced adipocyte lipolysis and promotes high-fat diet (HFD)-induced adipocyte dysfunction, liver lipotoxicity, and systemic insulin resistance. Conversely, in a mouse model with dox-inducible, adipocyte-specific overexpression of mDIC (mDICiOE), we observed suppression of adipocyte lipolysis both in vivo and ex vivo. mDICiOE mice are potently protected from liver lipotoxicity upon HFD feeding. Furthermore, they show resistance to HFD-induced weight gain and adipose tissue expansion with concomitant improvements in glucose tolerance and insulin sensitivity. Beyond our data in rodents, we found that human WAT SLC25A10 mRNA levels are positively correlated with insulin sensitivity and negatively correlated with intrahepatic triglyceride levels, suggesting a critical role of mDIC in regulating overall metabolic homeostasis in humans as well. CONCLUSIONS: In summary, we highlight that mDIC plays an essential role in governing adipocyte lipolysis and preventing liver lipotoxicity in response to a HFD. LAY SUMMARY: Dysfunctional fat tissue plays an important role in the development of fatty liver disease and liver injury. Our present study identifies a mitochondrial transporter, mDIC, which tightly controls the release of free fatty acids from adipocytes to the liver through the export of succinate from mitochondria. We believe this mDIC-succinate axis could be targeted for the treatment of fatty liver disease.
Authors: Christine M Kusminski; William L Holland; Kai Sun; Jiyoung Park; Stephen B Spurgin; Ying Lin; G Roger Askew; Judith A Simcox; Don A McClain; Cai Li; Philipp E Scherer Journal: Nat Med Date: 2012-09-09 Impact factor: 53.440
Authors: Matheus de Castro Fonseca; Carla J Aguiar; Joao Antônio da Rocha Franco; Rafael N Gingold; M Fatima Leite Journal: Cell Commun Signal Date: 2016-01-12 Impact factor: 5.712
Authors: Evanna L Mills; Kerry A Pierce; Mark P Jedrychowski; Ryan Garrity; Sally Winther; Sara Vidoni; Takeshi Yoneshiro; Jessica B Spinelli; Gina Z Lu; Lawrence Kazak; Alexander S Banks; Marcia C Haigis; Shingo Kajimura; Michael P Murphy; Steven P Gygi; Clary B Clish; Edward T Chouchani Journal: Nature Date: 2018-07-18 Impact factor: 49.962
Authors: Jack L Martin; Ana S H Costa; Anja V Gruszczyk; Timothy E Beach; Fay M Allen; Hiran A Prag; Elizabeth C Hinchy; Krishnaa Mahbubani; Mazin Hamed; Laura Tronci; Efterpi Nikitopoulou; Andrew M James; Thomas Krieg; Alan J Robinson; Margaret M Huang; Stuart T Caldwell; Angela Logan; Laura Pala; Richard C Hartley; Christian Frezza; Kourosh Saeb-Parsy; Michael P Murphy Journal: Nat Metab Date: 2019-09-30
Authors: Gang Li; Xin Li; Li Yang; Shuyue Wang; Yulin Dai; Baharan Fekry; Lucas Veillon; Lin Tan; Rebecca Berdeaux; Kristin Eckel-Mahan; Philip L Lorenzi; Zhongming Zhao; Richard Lehner; Kai Sun Journal: Life Sci Alliance Date: 2022-04-22
Authors: Reham Atallah; Juergen Gindlhuber; Wolfgang Platzer; Thomas Bärnthaler; Eva Tatzl; Wolfgang Toller; Jasmin Strutz; Sonja Rittchen; Petra Luschnig; Ruth Birner-Gruenberger; Christian Wadsack; Akos Heinemann Journal: Int J Mol Sci Date: 2021-11-07 Impact factor: 6.208
Authors: Derek Strassheim; Timothy Sullivan; David C Irwin; Evgenia Gerasimovskaya; Tim Lahm; Dwight J Klemm; Edward C Dempsey; Kurt R Stenmark; Vijaya Karoor Journal: Cells Date: 2021-11-29 Impact factor: 7.666
Authors: Zhuzhen Zhang; Jan-Bernd Funcke; Zhenzhen Zi; Shangang Zhao; Leon G Straub; Yi Zhu; Qingzhang Zhu; Clair Crewe; Yu A An; Shiuhwei Chen; Na Li; May-Yun Wang; Alexandra L Ghaben; Charlotte Lee; Laurent Gautron; Luke J Engelking; Prithvi Raj; Yingfeng Deng; Ruth Gordillo; Christine M Kusminski; Philipp E Scherer Journal: Cell Metab Date: 2021-06-25 Impact factor: 31.373